News
Company News: MGI and Curetis to Collaborate on NGS-based Infectious Disease Diagnostics
– Broad collaboration to develop a targeted Next-Generation Sequencing assay for microbial infections
– Workflow for native samples integrating MGI and Curetis instrumentation
– Curetis’ subsidiary Ares Genetics to provide assay design and data interpretation app
Company News: Anergis Announces Top Line Results from Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT
– Primary endpoint met: Combined Symptom and Medication Score in the AllerT 50 µg group is 7% lower than in the placebo group (p = 0.0047) over the entire birch pollen season
– Rhinoconjunctivitis Symptom Score in the AllerT 50 µg group is 14% lower than in the placebo group (p < 0.0001)
– Nighttime Nasal Symptom Score in the AllerT 50 µg group is 35% lower than in the placebo group (p<0.0001)
– Asthma Symptom and Medication Score in the AllerT 50 µg group is 29% lower than in the placebo group (p<0.0001)
Company News: BioNTech AG Enters into Licensing Agreement with CELLSCRIPT, LLC as it Advances Development of Messenger RNA Encoding Bispecific Antibodies and other Therapeutic Proteins
BioNTech AG, a fully integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it has entered into a broad and comprehensive non-exclusive patent licensing agreement with CELLSCRIPT, LLC covering nucleoside-modified messenger RNA (mRNA) for use in all in vivo applications, including therapeutic and non-therapeutic applications in humans and animals.
Company News: Results of Phase II Combination Trial of ISA101 and Nivolumab to be Presented at ESMO 2017
– Incurable HPV16+ solid tumors treated with therapeutic cancer vaccine plus checkpoint inhibitor
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced the presentation of the results of a clinical Phase II trial initiated by MD Anderson Cancer Center in collaboration with ISA and Bristol-Myers Squibb (NCT02426892) at ESMO 2017 (September 8-12, 2017, Madrid, Spain). In the trial, cancer patients with HPV16+ incurable solid tumors received a combination of ISA’s synthetic long-peptide (SLP) HPV-16 vaccine ISA101 and nivolumab, a monoclonal antibody acting as a PD-1 checkpoint inhibitor.